Gynecological Cancer Patients with Specific Wnt Mutations and High DKK1 Levels Respond Better to DKN-01, Trial Results Show

Gynecological Cancer Patients with Specific Wnt Mutations and High DKK1 Levels Respond Better to DKN-01, Trial Results Show
Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the Dickkopf-1 (DKK1) protein, or specific mutations in the Wnt signaling pathway, according to results of a Phase 2 clinical trial. Those findings highlight that the presence of Wnt-activating mutations and DKK1 levels may predict the effectiveness of DKN-01 in these patients. The trial results were shown in oral and poster presentations at the 2019 Annual Global Meeting of the International Gynecologic Cancer Society, held on Sept. 19–21 in Rio de Janeiro, Brazil. Wnt is an essential signaling pathway during embryonic development, but it is not active in most adult cells. Some Wnt mutations can reactivate the pathway, leading to high levels of DDK1 (a Wnt regulator), which are associated with uncontrolled cell growth and suppression of the immune response. High levels of DDK1, found in several types of cancer, are associated with more aggressive disease and poorer outcomes. DKN-01 is an immunotherapy that
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *